Ross\Johnson & Associates’s AbbVie ABBV Stock Holding History

Ross\Johnson & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.03K	Buy	16 +1	+7%	+$215	0.06%	57
2026 Q1	$3.26K	Sell	15 -2	-12%	-$444	0.06%	58
2025 Q4	$3.88K	Buy	17 +2	+13%	+$456	0.07%	55
2025 Q3	$3.47K	Hold	15	–	–	0.07%	58
2025 Q2	$2.78K	Sell	15 -5	-25%	-$929	0.06%	58
2025 Q1	$4.19K	Buy	20 +9	+82%	+$1.75K	0.07%	100
2024 Q4	$1.96K	Buy	+11	New	+$2.02K	0.05%	70

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ross\Johnson & Associates's ABBV Position: Q2 2026 in Review

Ross\Johnson & Associates increased its AbbVie (ABBV) stake by 6.7% in Q2 2026, buying an estimated $215 and bringing the position to 16 shares worth $4.03K. The position accounts for 0.06% of the portfolio, ranked #57.

Ross\Johnson & Associates first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.19K in Q1 2025. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Ross\Johnson & Associates held 16 shares of AbbVie worth $4.03K as of Q2 2026.
Ross\Johnson & Associates bought 1 AbbVie share in Q2 2026, an estimated $215.
AbbVie made up 0.06% of Ross\Johnson & Associates's portfolio in Q2 2026, its #57 holding.
Ross\Johnson & Associates first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
Ross\Johnson & Associates's AbbVie position peaked at $4.19K in Q1 2025.
4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.